PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

APOPTOSIS - PROGRAMMED CELL DEATH IN SOME PROSTATIC PATHOLOGIES
Article published in Urologia Polska 2000/53/3.

authors

Zbigniew Wolski, Tomasz Drewa
Katedra i Klinika Urologii Akademii Medycznej im. L. Rydygiera w Bydgoszczy
Kierownik: prof. dr hab. med. Z. Wolski

keywords

prostate programmed cell death (apoptosis)

summary

Programmed cell death occurs in process named apoptosis. Apoptosis takes
place in every cell during physiological or pathological state as well. The aim
of this paper is presentation of the newest achievement in the field of apoptotic
research regard to pathology of prostate. New possibilities to explain the
etiology of prostatic pathologic conditions, prevention and menagement of
BPH and carcinoma of prostate as well.

references

  1. [1] Agus, D. B., Cordon- Cardo, C, Fox, W., Drobnjak, M., Koff, A., Golde,
  2. D. W., Schwer, H. I.: Prostate cancer cell cycle regulators: response to androgen
  3. withdrawal and development of androgen independence. J. Nat. Cancer Inst. 1999,
  4. 91, 1869-1876.
  5. [2] Ahonen, T. J., Harkonen, P. L., Laine, J., Rui, H., Martikainen, P. M.,
  6. Nevalainen, M. T.: Prolaktin is a survival factor for androgen-deprived rat dorsal
  7. and lateral prostate epithelium in organ culture. Endocr. 1999,140, 5412-5421.
  8. [3] Blutt, S. R., McDonnell, T. J., Polek, T. C, Weigel, N. L.: Cakitnol-induced
  9. apoptosis in LNCaP cells is blocked by overexpression ofBcl-2. Endocr. 2000,141,
  10. 107.
  11. [4] Bostwik, D. G., Neumann, R., Qian, J., Cheng, L.: Reuersibility of prostatic
  12. intraepithe³ial neoplasia: Implications for chemoprevention. Eur. Urol. 1999, 35,
  13. 492-495.
  14. [5] Cardillo, M., Berchem, G., Tarkington, M. A., Krajewski, S., Krajewski,
  15. M., Reed, J.-C, Tehan, T., Ortega, L., Lagê, J., Gelmann, E. P: Resistance to
  16. apoptosis and up regulation of Bcl-2 in benign prostatic hyperplasia after androgen
  17. deprwation. J. Urol. 1997,158, 212-216.
  18. [6] Chen, Y. R., Zhou, G., Tan, T. H.: c-Jun N-terminal kinase mediates apoptotic signah
  19. ing induced by N-(4-hydroxyphenyl)retinamide. Mol. Pharmacol. 1999,56,1271-
  20. 1279.
  21. [7] Choi, N. G., Sohn, J. H., Park, H. W., Jung, T. Y.: Apoptosis and nuclear
  22. shapes in benign prostate hyperplasia and prostate adenocarcinoma: Comparison with
  23. and relation to Gleason score. Int. J. Urol. 1999, 6,13-18.
  24. [8] Chon, J. K., Borkowski, A., Partin, A. W., Isaacs, J. T., Jacobs, S. C,
  25. Kyprianou, N.: Alpha l-adrenoceptor antagonists terazosin anddoxazosin induce
  26. prostate apoptosis without affecting cell proliferation in patients with benign prostat-
  27. ic hyperplasia. J. Urol. 1999, 161, 2002-2008.
  28. [9] Claus, S., Berges, R., Senge, T., Schulze, H.: Celli kinetic in epithelium and
  29. strorna of benign prostatic hyperplasia. J. Urol. 1997,158, 217-221.
  30. [10] Colombel, M., Vacherot, F., Diez, S. G., Fontaine, E., Buttyan, R., Chopin,
  31. D.: Zonal variation of apoptosis and proliferation in the normal prostate and in
  32. benign prostatic hyperplasia. Br. J. Urol. 1998, 82, 380-385.
  33. [11] Costa-Pereira, A. P., Cotter, T. G.: Camptothecin sensitizes androgen-indepen-
  34. dent prostate cancer cells to anti-F as-induced apoptosis. Br. J. Cancer 1999,80,371-
  35. 378.
  36. [12] Garzotto, M., Haimovitz-Friedman, A., Liao, W. C, White-Jones, M,
  37. Huryk, R., Heston, W. D., Cardon-Cardo, C, Kolesnick, R., Fuks, Z.:
  38. Reversal of radiation resistance in LNCaP cells by targeting apoptosis through cera-
  39. mide synthase. Cancer Res. 1999, 15, 5194-5201.
  40. [13] Gjertsen, B. T., Logothetis, Ch. J., McDonnell, T. J.: Molecular regulation of
  41. cell death and the rapeutic strategies for cell death induction in prostate carcinoma.
  42. Cancer Metast. Rev. 1999,17, 345-351.
  43. [14] Gleave, M. E., Miayake, H., Goldie, J., Nelson, C, Tolcher, A.: Targeting
  44. bcl-2 gene using to delay androgen-independent progression and enhance chemosen-
  45. sitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides. Urol. 1999,
  46. 54 (6A Suppl.), 36-46.
  47. [15] Gleave, M., Tolcher, A., Miyake, H., Nelson, C, Brown, B., Beraldi, E.,
  48. Goldie, J.: Progression to androgen independence is delayed by adjuvant treatment
  49. with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate
  50. tumor model. Clin. Cancer Res. 1999, 5, 2891-2898.
  51. [16] Gosden, R., Spears, N.: Programmed cell death in the reproductive system. Br.
  52. Med. Bull. 1997, 5, 644-661.
  53. [17] Grace, M. J., Xie, L., Musco, M. L., Cui, S., Gumani, M., DiGiacomo, R.,
  54. Chang, A., Indelicato, S., Syed, J., Johnson, R., Nielsen, L. L.: The use of
  55. laser scanning cytometry to assess depth of penetration ofadenovirus p53 gene ther-
  56. apy in human xenograft biopsies. Am. J. Path. 1999,155,1869-1878.
  57. [18] Grant, E. S., Ross, M. B., Ballard, S., Naylor, A., Habib, F. K.: The insulin-
  58. like growth type I receptor stimulates growth and suppresses apoptosis in prostatic
  59. stromal cells. J. Clin. Endocr. Metab. 1998, 83, 3252-3257.
  60. [19] Haussler, O., Epstein, J. I., Amin, M. B., Heitz, P. U., Hailemariam, S.:
  61. Cell proliferation, apoptosis, oncegene, and tumor suppresor gene status in adenosis
  62. with comparison to benign prostatic hyperplasia, prostatic intraepithelial neoplasia,
  63. and cancer. Hum. Path. 1999, 30,1077-1086.
  64. [20] Kajiwara, T., Takeuchi, T., Ueki, T., Moriyama, N., Ueki, K., Kakizoe, T.,
  65. Kawabe, K.: Effect of Bcl-2 overexpression in human prostate cancer cells in vitro
  66. and in vivo. Int. J. Urol. 1999, 6, 520-525.
  67. [21] Kelloff, G. J., Lieberman, R., Steele, V. E., Boone, Ch. W., Lubet, R. A.,
  68. Kopelovitch, L., Malone, W. A., Crowell, J. A., Sigman, C. C: Chemopre-
  69. vention of prostate cancer: concepts and strategies. Eur. Urol. 1999,35,342-350.
  70. [22] Krajewska, M., Krajewski, S., Epstein, J. I., Shabaik, A., Sauvageot, J.,
  71. Song, K., Kitada, S., Reed, J. C: Immunohistochemical analysis of bcl-2, bax, bcl-
  72. X, and mci-1 expression in prostate cancers. Am. J. Path. 1996,148,1567-1576.
  73. [23] Krajewski, S., Krajewska, M., Shabaik, A., Miyashita, T., Wang, H. G.,
  74. Reed, J. C: Immunohistological determination of in vivo distribution of bax, a
  75. dominant inhibitor of bcl-2. Am. J. Path. 1994,145,1323-1336.
  76. [24] Kwong, J., Choi, H. E., Huang, Y., Chan, F. L.: Ultrastructural and biochem-
  77. ical observations on the early changes in apoptotic epithelial cells of the rat prostate
  78. induced by castration. Cell Tiss. Res. 1999, 298,123-136.
  79. [25] Kyprianou, N., Litvak, J. P., Borkowski, A., Alexander, R., Jacobs, S. C:
  80. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J. Urol.
  81. 1998, 159, 1810-1815.
  82. [26] Kyprianou, N., Tu, H., Jacobs, S. C: Apoptotic versus proliferative activities
  83. in human benign prostatic hyperplasia. Hum. Path. 1996, 27, 668-675.
  84. [27] Lee, S. H., Shin, M. S., Park, W. S., Kim, S. Y., Dong, S. M., Lee, H. K.,
  85. Park, J. Y., Oh, R. R., Jang, J. J., Lee, I. Y., Yoo, N. J.: Immunohistochemical
  86. analysis of fas ligand expression in normal human tissues. APMIS1999,107,1013-
  87. 1019.
  88. [28] Lee, C, Sintich, S. M., Mathews, E. P., Shah, A. H., Kundu, S. D., Perry,
  89. K. T., Cho, J. S., Ilio, K. Y., Cronauer, M. V., Janulis, L., Sensibar, J. A.:
  90. Transforming growth factor- beta in benign and malignant prostate. Prostate 1999,
  91. 39, 285-290.
  92. [29] Li, C. J., Li, Y. Z., Pinto, A. V., Pardee, A. B.: Potent inhibition of tumor
  93. survival in vivo by beta-lapachone plus taxoh combining drugs imposes different
  94. artificial checkpoints. Proc. Nat. Acad. Sci. 1999, 96,1369-1374.
  95. [30] Lim, J. T., Piazza, G. A., Han, E. K., Delohery, T. M., Li, H., Finn, T. S.,
  96. Buttyan, R., Yamamoto, H,, Sperl, G. J., Brendel, K., Gross, P. H., Pam-
  97. ukcu, R., Weinstein, I. B.: Sulindac derivatives inhibit growth and induce apopto-
  98. sis in human prostate cancer cell lines. Biochem. Pharm. 1999,58,1097-1107.
  99. [31] Lu, S., Tsai, S. Y., Tsai, M. J.: Molecular mechanisms of androgen-independent
  100. growth of human prostate cancer LNCaP-AI cells. Endocr. 1999,140, 5054-5059.
  101. [32] Magi-Galluzi, C.,'Montironi, R., Cangi, M. G., Wishnow, K., Loda, M.:
  102. Mitogen-activated protein kinases and apoptosis in PIN. Virchows Arch. 1998,
  103. 432, 407-413.
  104. [33] McConkey, D. J., Greene, G., Pettaway, C. A.: Apoptosis resistance increases
  105. with metastatic potential in cells of the human LNCaP prostate carcinoma line. Can-
  106. cer Res. 1996, 56, 5594-5599.
  107. [34] Mikuz, G.: Pathology of prostate cancer. Old problems and new facts. Adv. Clin.
  108. Path. 1997,1, 21-34.
  109. [35] Miller, L. J., Marx, J.: Apoptosis. Science 1998, 281,1301.
  110. [36] Montironi, R., Magi-Galluzzi, C, Fabris, G.: Apoptotic bodies in prostatic
  111. intraepithelial neoplasia and prostatic adenocarcinoma following total androgen ab-
  112. lation. Path. Res. Pract. 1995,197, 873-880.
  113. [37] Montironi, R., Magi-Galluzzi, C. M., Marina, S., Diamanti, L.: Quantita-
  114. tive characterization of the frequency and location of cell proliferation and death in
  115. prostate pathology. J. Cell Biochem. Suppl. 1994,19, 238-245.
  116. [38] Montironi, R., Magi-Galluzzi, C, Scarpelli, M., Giannulis, I., Diaman-
  117. ti, L.: Occurrence of cell death (apoptosis) in prostatic intraepithelial neoplasia. Vir-
  118. chows. Arch. Path. Anat. Histopath. 1993, 423, 351-357.
  119. [39] Moul, J. W.: Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate
  120. cancer after radical prostatectomy. Eur. Urol. 1999, 35, 399-407.
  121. [40] Myers, R. B., Grizzle, W. E.: Changes in biomarker expression in the develop-
  122. ment of prostatic adenocarcinoma. Biotech. Histochem. 1977, 72,86-95.
  123. [41] Nickerson, T., Pollak, M.: Bicalutamide (Casodex)-induced prostate regression
  124. involves increased expression of genes encoding insulin-like growth factor binding
  125. proteins. Urology 1999, 54, 1120-1125.
  126. [42] Nupponen, N., Visakorpi, T.: Molecular biology of progression of prostate can-
  127. cer. Eur. Urol. 1999, 35, 351-354.
  128. [43] Powell, W. C, Fingletpn, B., Wilson, C. L., Boothby, M., Matrisian, L.
  129. M.: The metalloproteinase matrilysin proteolytically generates active soluble fas ligand
  130. and potentiates epithelial cell apoptosis. Curr. Biol. 1999, 9,1441-1447.
  131. [44] Radziszewska, E.: Fizjologiczna rolaapoptozy. Post. Biol. Kom. 1995,22,247-
  132. 261.
  133. [45] Rajah, R., Khare, A., Lee, P. D., Cohen, P.: Insulin-like growth factor-binding
  134. protein-3 is partially responsible for high-serum-induced apoptosis in PC-3 prostate
  135. cancer cells. J. Endocr. 1999,163,487-494.
  136. [46] Reuter, V. R.: Pathological changes in benign and malignant prostatic tissue follow-
  137. ing androgen deprovation therapy. Urology 1997, 49 (3A Suppl.), 16-22.
  138. [47] Rittmaster, R. S., Nonnan, R. W., Thomas, L. N., Rowden, G.: Evidence for
  139. atrophy and apoptosis in the prostates of men given finasteride. J. Clin. Endrocrinol.
  140. Metab. 1996, 81, 814-819.
  141. [48] Rittmaster, R. S., Thomas, L. N., Wright, A. S., Murray, S. K., Carlson,
  142. K., Douglas, R. C, Yung, J., Messich, M., Bell, D., Lazier, C. B.: Theutility
  143. of tissue transglutaminase as a marker of apoptosis during treatment and progression
  144. of prostate cancer. J. Urol. 1999,162, 2165-2169.
  145. [49] Rokhlin, O. W., Bishop, G. A., Hostager, B. S., Waldschmidt, T. I., Si-
  146. dorenko, S. P., Pavloff, N., Kiefer, M. C, Umansky, S. R., Glover, R. A.,
  147. Cohen, M. B.: Fas-mediated apoptosis in human prostatic carcinoma cell lines.
  148. Cancer Res. 1997, 57f 1758-1768.
  149. [50] Rokhlin, O. W., Glover, R.A., Cohen, M. B.: Fas-mediated apoptosis in human
  150. prostatic carcinoma cell lines occurs via activation ofcaspase-8 and caspase-7. Can-
  151. cer Res. 1998, 58, 5870-5875.
  152. [51] Rokhlin, O. W., Hostager, B. S., Bishop, G. A., Sidorenko, S. P., Glover,
  153. R. A., Gudkov, A. V., Cohen, M. B.: Dominant nature of the resistance tofas-and
  154. tumor necrosis factor-alfa-mediated apoptosis in human prostatic carcinoma cell lines.
  155. Cancer Res. 1997, 57, 3941-3943.
  156. [52] Rose, D. P., Connolly, J. M.: Omega-3 fatty acids as cancer chemopreventive
  157. agents. Pharm. Ther. 1999, 83, 217-244
  158. [53] Riuz, L., Miguel, A., Diaz-Laviada, I.: Delta ^-tetrahydrocannabinol induced
  159. apoptosis in human prostate PC- 3 cells via a receptor-independent mechanism. FEBS
  160. Lett. 1999, 458, 400-404.
  161. [54] Savill, J.: Recognition and phagocytosis of cells undergoing apoptosis. Br. Med.
  162. Bull. 1995, 53, 491-508.
  163. [55] Shibata, M. A., Ward, J. M., Devor, D. E., Liu, M. L., Green, J. E.: Progres-
  164. sion of prostatic intraepithelial neoplasia to invasive carcinoma in C3(l)/SV40 large
  165. T antigen transgenic mice: histopathological and molecular biological alterations.
  166. Cancer Res. 1999, 56, 4894-4903.
  167. [56] Shim, M., Cohen, P.: IGFs and human cancer: implications regarding the risk of
  168. growth hormone therapy. Horm. Res. 1999,51 (Suppl. S3), 42-51.
  169. [57] Srikanth, S., Franklin, C. C, Duke, R. C, Kraft, R. S.: Human DU145
  170. prostate cancer cells overexpressing mitogen-activated protein kinase phosphatase -1
  171. are resistant to fas ligand-induced mitochondrial perturbations and cellular. Mol.
  172. Cell Biochem. 1999,199,169-178.
  173. [58] Stattin, P., Damber, J. E., Karlberg, L., Nordgren, H., Bergh, A.: Bcl-2
  174. immunoreaclivity in prostate tumorgenesis in relation to prostatic intraepithelial
  175. neoplasia, grade, hormonal status, metastatic growth and survival. Urol. Res. 1996,
  176. 24, 257-264.
  177. [59] Stattin, P., Westin, P., Damber, J. H., Bergh, A.: Short-term cellular effects
  178. induced by castration therapy in relation to clinical outcome in prostate cancer. Br. J.
  179. Cancer 1998, 77, 670-675.
  180. [60] Steinberg, J., Oyasu, R., Lang, S., Sinlich, S., Rademaker, A., Lee, C,
  181. Kozlowski, J. M., Sensibar, J. A.: Intracellular levels of'SGP-2 (Clusterin) corre-
  182. late with tumor grade in prostate cancer. Clin. Cancer Res. 1997, 3,1707-1711.
  183. [61] Steller, H.: Mechanism and genes of cellular suside. Science 1995, 267, 1445-
  184. 1449.
  185. [62] Sumimoto, M., Tachibana, M., Nakashima, J., Murai, M., Miyajima, A.,
  186. Kimura, F., Hayakawa, M., Nakamura, H.: An essential role for nuclear factor
  187. kappa B in preventing TNF-alfa induced cell death in prostate cancer cells. J. Urol.
  188. 1999, 161, 674-679.
  189. [63] Sun, Z. Y., Wu, H. Y., Wang, M. Y., Tu, Z. H.: The mechanism ofepristeride
  190. agains benign prostatic hyperplasia. Eur. J. Pharm. 1999, 371, 227-233.
  191. [64] Szende, B., Romics, I., Torda, I., Bely, M., Szegedi, Z., Lovasz, S.: Apopto-
  192. sis, mitosis, p53, bcl(2), Ki-67 and clinical outcome in prostate carcinoma treated by
  193. androgen ablation. Urol. Int. 1999, 63,115-119.
  194. [65] Taboga, S. R.: Apoptosis as a mediator of hyperplastic recovery in human prostate
  195. lesions: cytochemical and immunocytochemical evaluation. Cytobios. 1999, 99,19-
  196. 26.
  197. [66] Tang, D. G., Li, L., Chopra, D. P., Porter, A. T.: Extended survivability of
  198. prostate cancer cells in the absence of tropic factors: incresed proliferation, evansion of
  199. apoptosis, and the role of apoptosis proteins. Cancer Res. 1998, 58, 3466-3479.
  200. [67] Thornberry, N. A., Lazebnik, Y.: Caspases: enemies within. Science 1998,281,
  201. 1312-1316.
  202. [68] Wang, X. Z., Beebe, J. R., Pwiti, L. Bielawska, A., Smyth, M. J.: Aberrant
  203. sphingolipid signaling is involved in the resistance of prostate cancer cell lines to
  204. chemotherapy. Cancer Res. 1999, 59, 5842-5848.
  205. [69] Webber, M. M., Bello-De-Ocampo, D., Quader, S., Deocampo, N. D., Met-
  206. calfe, W. S., Sharp, R. M.: Modulation of the malignant phenotype of human
  207. prostate cancer cells by N-(4-hydroxyphenyl) retinamide (4-HPR). Clin. Exp. Metast.
  208. 1999, 17, 255-263.'
  209. [70] Wheeler, T. M., Rogers, E., Aihara, M., Scardino, P. T., Thompson, T. C:
  210. Apoptotic index as a biomarker in prostatic intraepithelial neoplasia (PIN) and pros-
  211. tate cancer. J. Cell Biochem. Suppl. 1994,19, 202-207.
  212. [71] Whelan, P.: Retinoids in chemoprevention. Eur. Urol. 1999, 35, 424-428.
  213. [72] Yang, G., Timme, T. L., Park, S. H., Wu, X., Wyllie, M. G., Thompson, T.
  214. C: Transformating growth factorbeta I transduced mouse prostate reconstituctions:
  215. II. Induction of apoptosis by doxazosin. Prostate 1997, 33,157-163.
  216. [73] Ying, S. Y., Chuong, C. M., Lin, S.: Suppression ofactivin-induced apoptosis by
  217. novelantisense strategy in human prostate cancer cells. Biochem. Biophys. Res.
  218. Commun. 1999, 26, 669-673.